Treatment of cerebral cavernous malformations and cerebral aneurysms with Rho kinase inhibitors

1. A method of treating a cerebral cavernous malformation (CCM) in a mammal, comprising:

administering to the mammal a therapeutically effective amount of a pharmaceutical formulation comprising BA-1049; and

detecting a reduction in the number or size of CCM lesions and/or maturation of simple CCM lesions into complex, clinically significant lesions relative to the number, size, and/or maturity of CCM lesions before administration.

2. The method of claim 1 , wherein the BA-1049 is a racemic mixture.

3. The method of claim 1 , wherein the BA-1049 is the (R) enantiomer.

4. The method of claim 1 , wherein the pharmaceutical formulation is administered orally.

5. The method of claim 4 , wherein the pharmaceutical formulation is in the form of a tablet or a capsule.

6. The method of claim 1 , wherein the method further comprises administering to the mammal a therapeutically effective amount of at least a second Rho kinase inhibitor other than BA-1049 (racemic mixture) or BA-1049 (R).

7. The method of claim 6 , wherein the at least a second Rho kinase inhibitor is BA-1042, BA-1043, BA-1044, BA-1050, BA-1051, C3, KD025, Rhopressa, Roclatan, AR-13533, Fasudil, HA-1077, Radicut, Azandoile 1, BF66851, BF66852, BF66853, and/or Y27632.

8. The method of claim 1 , wherein the pharmaceutical formulation further comprises at least a second Rho kinase inhibitor other than BA-1049 (racemic mixture) or BA-1049 (R).

9. The method of claim 8 , wherein the at least a second Rho kinase inhibitor is BA-1042, BA-1043, BA-1044, BA-1050, BA-1051, C3, KD025, Rhopressa, Roclatan, AR-13533, Fasudil, HA-1077, Radicut, Azandoile 1, BF66851, BF66852, BF66853 and/or Y27632.

10. The method of claim 4 , wherein the pharmaceutical formulation is in the form of a tablet.